Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Saccharomyces, particularly Saccharomyces boulardii, has scientific support for its use as an adjunct in the prevention and treatment of certain bacterial infections, especially those affecting the gastrointestinal tract. Clinical studies and meta-analyses have demonstrated that S. boulardii can reduce the risk of antibiotic-associated diarrhea, including Clostridioides difficile infection, by restoring healthy gut flora and inhibiting the growth or activity of pathogenic bacteria. The mechanisms proposed include production of antimicrobial substances, enhancement of mucosal immunity, and competitive exclusion of pathogens. Several randomized, placebo-controlled trials have shown benefits in both adults and children, although the effect size varies depending on the specific infection and population studied.

It is important to note that the scientific evidence is strongest for gut-related bacterial infections, not for systemic or non-gastrointestinal infections. The evidence base is moderate (rated 3 out of 5), as most studies demonstrate efficacy as an adjunct rather than a sole therapy, and effectiveness appears to be strain-specific (primarily S. boulardii rather than other Saccharomyces species). Safety is generally good, but caution is advised in immunocompromised individuals. There is little to no evidence supporting the use of Saccharomyces for bacterial infections outside the gastrointestinal tract.

More about Saccharomyces (unspecified)
More about Infection (bacterial)

Other ingredients used for Infection (bacterial)

Other health conditions supported by Saccharomyces (unspecified)

Products containing Saccharomyces (unspecified)